ASKA Pharmaceutical Holdings Co., Ltd. ( (JP:4886) ) has issued an announcement.
ASKA Pharmaceutical Co., Ltd. has initiated a Phase I/II clinical trial in Japan for a new drospirenone agent, LPRI-CF113, targeting dysmenorrhea. This trial marks an expansion of ASKA’s partnership with Insud Pharma, strengthening its position in the obstetrics and gynecology market and potentially improving women’s health outcomes.
More about ASKA Pharmaceutical Holdings Co., Ltd.
ASKA Pharmaceutical Holdings Co., Ltd. is a specialty pharmaceutical company focusing on the field of obstetrics and gynecology. It aims to enhance its product lineup and contribute to women’s health and quality of life through innovative drug development.
YTD Price Performance: 4.81%
Average Trading Volume: 52,264
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: Yen62.51B
For a thorough assessment of 4886 stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com